• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Morning Movers: PFE, VRX, VIAB, FL, UA

Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
By ANDERS KEITZ Aug 22, 2016 | 08:13 AM EDT
Stocks quotes in this article: PFE, MDVN, VRX, VIAB, CBS, FL, UA, ZTS

U.S. futures were priced for a lower opening on Monday ahead of this week's annual Fed monetary policy symposium in Jackson Hole, Wyo. European markets were all showing losses with a few hours until those markets close. Meanwhile, the Asian markets finished mixed, with the Nikkei and the Hang Seng showing small gains.

Crude oil was slipping Monday morning, with Brent Crude down 3% and West Texas Intermediate down 2.7%. Prices were dropping after Morgan Stanley analyst Adam Longson wrote in a research note Monday that oil prices may continue to fluctuate in the lead up to the informal meeting of OPEC member countries in Algeria at the end of September. Longson believes that a "meaningful OPEC production agreement" is highly unlikely, citing too many headwinds and logistical challenges. 

Pfizer (PFE) shares were sinking slightly in early trading after agreeing to acquire Medivation (MDVN) for $81.50 per share in cash, which represents a total enterprise value of approximately $14 billion. MDVN shares skyrocketed by nearly 20% on the news. The boards of both companies have unanimously approved the merger, which is expected to be complete in the third or fourth quarter. Pfizer does not anticipate the transaction to affect its current 2016 financial guidance. "The addition of Medivation will strengthen Pfizer's Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term," said Pfizer CEO Ian Read in a statement.

Shares of Valeant (VRX) were up about 4% in premarket trading on news that the company named a new CFO. The Canadian drugmaker named Paul Herendeen, former Zoetis (ZTS) CFO, to fill the position immediately. Herendeen replaces Robert Rosiello, who will remain at Valeant as executive vice president. "[Herendeen's] prior experience as a public company CFO, strong operational focus and disciplined approach to financial management make him the ideal choice to lead our finance function as we execute on our plans to stabilize and transform the company," said CEO Joseph Papa in a statement. "As we move forward, Paul and the other members of the executive management team will play vital roles in shaping the new Valeant."

Viacom (VIAB) made it official this weekend: CEO Philippe Dauman is out. In a statement issued on Saturday, Dauman will step down immediately as president and CEO, but will continue as a non-executive chairman until Sept. 13. Viacom's COO Thomas Dooley was named interim CEO through Sept. 30. Under the terms of the settlement, all lawsuits among them will be terminated. Viacom is also creating an expanded board of directors to include the five director elected in June by National Amusements (Sumner Redstone's company holds about 80% stake in both Viacom and CBS (CBS) .

Finally, with back-to-school season here, one Citi analyst is saying to put Foot Locker (FL) and Under Amour (UA) on your shopping list. Citi's Kate McShane believes that while shopping trends remain challenging, the athletic area continues to be an "intact" industry that can still capitalize on increased "casualization" and ongoing innovation. McShane picked Foot Locker as her top pick in the space. (Under Armour is a holding in the Growth Seeker portfolio). 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Energy | Consumer Discretionary | Futures | Mergers and Acquisitions

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:40 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login